Breast Cancer Classification and Prognosis Based on Gene Expression Profiles from a Population-based Study

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2003 Aug 15

PMID 12917485

Citations 725

Authors

Christos Sotiriou

Soek-Ying Neo

Lisa M McShane

Edward L Korn

Philip M Long

Amir Jazaeri

Philippe Martiat

Steve B Fox

Adrian L Harris

Edison T Liu

Affiliations

Soon will be listed here.

Abstract

Comprehensive gene expression patterns generated from cDNA microarrays were correlated with detailed clinico-pathological characteristics and clinical outcome in an unselected group of 99 node-negative and node-positive breast cancer patients. Gene expression patterns were found to be strongly associated with estrogen receptor (ER) status and moderately associated with grade, but not associated with menopausal status, nodal status, or tumor size. Hierarchical cluster analysis segregated the tumors into two main groups based on their ER status, which correlated well with basal and luminal characteristics. Cox proportional hazards regression analysis identified 16 genes that were significantly associated with relapse-free survival at a stringent significance level of 0.001 to account for multiple comparisons. Of 231 genes previously reported by others [van't Veer, L. J., et al. (2002) Nature 415, 530-536] as being associated with survival, 93 probe elements overlapped with the set of 7,650 probe elements represented on the arrays used in this study. Hierarchical cluster analysis based on the set of 93 probe elements segregated our population into two distinct subgroups with different relapse-free survival (P < 0.03). The number of these 93 probe elements showing significant univariate association with relapse-free survival (P < 0.05) in the present study was 14, representing 11 unique genes. Genes involved in cell cycle, DNA replication, and chromosomal stability were consistently elevated in the various poor prognostic groups. In addition, glutathione S-transferase M3 emerged as an important survival marker in both studies. When taken together with other array studies, our results highlight the consistent biological and clinical associations with gene expression profiles.

Citing Articles

Circadian clock features define novel subtypes among breast cancer cells and shape drug sensitivity.

Ector C, Didier J, De Landtsheer S, Nordentoft M, Schmal C, Keilholz U Mol Syst Biol. 2025; .

PMID: 39994450 DOI: 10.1038/s44320-025-00092-7.

The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype.

Turova P, Kushnarev V, Baranov O, Butusova A, Menshikova S, Yong S NPJ Breast Cancer. 2025; 11(1):19.

PMID: 39979291 PMC: 11842814. DOI: 10.1038/s41523-025-00723-0.

Molecular heterogeneity and MYC dysregulation in triple-negative breast cancer: genomic advances and therapeutic implications.

Priya , Kumar A, Kumar D 3 Biotech. 2025; 15(1):33.

PMID: 39777154 PMC: 11700964. DOI: 10.1007/s13205-024-04195-0.

An insight into the therapeutic effects of isoliquiritigenin in breast cancer.

Sharma D, Dhobi M, Lather V, Pandita D Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9503-9519.

PMID: 39007925 DOI: 10.1007/s00210-024-03282-6.

Omada: robust clustering of transcriptomes through multiple testing.

Kariotis S, Tan P, Lu H, Rhodes C, Wilkins M, Lawrie A Gigascience. 2024; 13.

PMID: 38991852 PMC: 11238428. DOI: 10.1093/gigascience/giae039.

References

El-Tanani M, GREEN C . Interaction between estradiol and growth factors in the regulation of specific gene expression in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol. 1997; 60(5-6):269-76. DOI: 10.1016/s0960-0760(96)00226-9. View

Hoch R, Thompson D, Baker R, Weigel R . GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer. 1999; 84(2):122-8. DOI: 10.1002/(sici)1097-0215(19990420)84:2<122::aid-ijc5>3.0.co;2-s. View

Liu E, Sotiriou C . Defining the galaxy of gene expression in breast cancer. Breast Cancer Res. 2002; 4(4):141-4. PMC: 138733. DOI: 10.1186/bcr438. View

Jallepalli P, Lengauer C . Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer. 2002; 1(2):109-17. DOI: 10.1038/35101065. View

Pinder S, Murray S, Ellis I, Trihia H, Elston C, Gelber R . The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer. 1998; 83(8):1529-39. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

McShane L, Radmacher M, Freidlin B, Yu R, Li M, Simon R . Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics. 2002; 18(11):1462-9. DOI: 10.1093/bioinformatics/18.11.1462. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Sotiriou C, Khanna C, Jazaeri A, Petersen D, Liu E . Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn. 2002; 4(1):30-6. PMC: 1906976. DOI: 10.1016/S1525-1578(10)60677-0. View

10.

Kerbel R, Cornil I, Theodorescu D . Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis. Cancer Metastasis Rev. 1991; 10(3):201-15. DOI: 10.1007/BF00050792. View

11.

West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R . Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A. 2001; 98(20):11462-7. PMC: 58752. DOI: 10.1073/pnas.201162998. View

12.

Tye B . MCM proteins in DNA replication. Annu Rev Biochem. 2000; 68:649-86. DOI: 10.1146/annurev.biochem.68.1.649. View

13.

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

14.

Polakis P . Wnt signaling and cancer. Genes Dev. 2000; 14(15):1837-51. View

15.

Ugolini F, Charafe-Jauffret E, Bardou V, Geneix J, Adelaide J, Penault-Llorca F . WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene. 2001; 20(41):5810-7. DOI: 10.1038/sj.onc.1204706. View

16.

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

17.

Desai K, Xiao N, Wang W, Gangi L, Greene J, Powell J . Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A. 2002; 99(10):6967-72. PMC: 124512. DOI: 10.1073/pnas.102172399. View

18.

Prevot D, Morel A, Voeltzel T, Rostan M, Rimokh R, Magaud J . Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: involvement in estrogen receptor alpha signaling pathway. J Biol Chem. 2001; 276(13):9640-8. DOI: 10.1074/jbc.M008201200. View

19.

Parkes A, Speirs V . British Cancer Research Meeting, 30 June-3 July 2002, Glasgow. Breast Cancer Res. 2002; 4(5):202-4. PMC: 138745. DOI: 10.1186/bcr453. View

20.

Fidler I . Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev. 1986; 5(1):29-49. DOI: 10.1007/BF00049529. View